1型糖尿病治疗的未来
Anette-Gabriele Ziegler1, Eda Cengiz2, Thomas W H Kay3
1Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany; School of Medicine and Health, Forschergruppe Diabetes at Klinikum rechts der Isar, Technical University of Munich and TUM University Hospital, Munich, Germany.
1型糖尿病的新疗法正在出现,包括延迟发病的免疫疗法和维护和替代β细胞的先进疗法. 葡萄糖监测和胰岛素输送方面的创新旨在改善长期管理和生活质量.
科学领域:
- 免疫学
- 内分泌学
- 复原医学
背景情况:
- 一型糖尿病的治疗正在迅速推进.
- 通过查及改变疾病的治疗方法进行早期诊断变得更加容易.
- 贝塔细胞替代疗法正在超越传统的移植.
研究的目的:
- 审查最近1型糖尿病管理的突破.
- 突出新型免疫疗法,β细胞替代策略和葡萄糖调节技术.
- 讨论这些创新对患者治疗结果和生活质量的潜在影响.
主要方法:
- 对新兴免疫疗法,如特利祖马布的审查.
- 探索源自干细胞的β细胞疗法和生物工程方法.
- 对自动注射胰岛素和新一代胰岛素的进展进行评估.
主要成果:
- 一种免疫疗法Teplizumab已被批准用于推迟1型糖尿病的临床发展.
- 来自干细胞的β细胞和生物工程为β细胞的替代提供了新的途径,可能减少免疫抑制需求.
- 自动化胰岛素输送系统和新型胰岛素可以增强血糖控制并最大限度地降低血糖波动.
结论:
- 转变性治疗为治疗1型糖尿病提供了新的希望.
- 免疫疗法,β细胞替代和葡萄糖调节方面的创新有望改善长期结果.
- 这些先进疗法的广泛实施仍然是一个重大挑战.
更多相关视频
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
相关概念视频
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
